RAPTOR AI® VERSION 2.0
Next-generation AI platform RAPTOR AI® VERSION 2.0
A next-generation AI platform that supports candidate indication discovery, mechanism-of-action interpretation, and new modality development based on Asian multi-omics data and automated experimental infrastructure.
RAPTOR AI® 2.0, which advances existing drug-disease matching capabilities, combines multi-omics data analysis, automated workflows, and a new modality interpretation engine to deliver practical value across the R&D decision-making process, from indication discovery onward.
CORE FEATURES
Core Functions
Core Features 01
Indication Discovery
Discovery of new indications for candidate compounds and drug-disease matching
Core Features 02
Mechanism-of-Action Interpretation
Multi-omics-based analysis of mechanisms of action and molecular pathways
Core Features 03
Advanced Multi-omics Analysis
Integrated transcriptomics, proteomics, and metabolomics analysis workflow
Core Features 04
Next-generation Modality Support
Analysis engine for new modalities such as ADCs, bispecific antibodies, and TPD
SMART WORKFLOW
Multi-omics integrated analysis platform
Oncocross's next-generation R&D platform combining multi-omics integrated analysis, automated workflows, and a new modality interpretation engine
Spatial proteomics-based co-target discovery
(ADCs, bispecific/multispecific antibodies)
We precisely identify co-target candidates that are physically and biologically adjacent to the target protein.
It can be used in antibody-based drug development, including ADCs, for target localization, PPI, and interpretation of neighboring protein networks.
AI-based on-/off-target prediction
(TPD and other next-generation modalities)
Using AI models, we predict a drug's on-target effects, off-target risks, MoA, and toxicity-related signals. We provide decision-making data for candidate optimization and drug development risk management.
DATA & TECHNOLOGY
Data and Technology Foundation
Asian Multi-omics Database
Securing East Asia-specific analytical strengths with Asian patient-based training data
Spatial Proteomics
Supporting precise mechanism interpretation through analysis of spatial protein distribution within tissues
Deep Plasma Proteomics
Enabling non-invasive data generation through blood-based deep proteomics analysis
Automated experimental infrastructure
Automated workflow foundation for data generation and validation
BUSINESS SIGNIFICANCE
Business Significance
Candidate Evaluation Support
Data-driven analysis that supports candidate evaluation and reduction of development risks
New Modality Platform
A core interpretation platform for the development process of next-generation modalities such as ADCs, bispecific antibodies, and TPD
Closed-loop Expansion
Expandable into a closed-loop structure connecting AI prediction and autonomous experimental infrastructure
Global Platform Infrastructure
Potential to evolve into platform infrastructure for global drug discovery
Together with Oncocross, we create new opportunities in drug discovery, diagnostics,
and data-driven expansion.
Let's Build the Next Possibility in Precision Medicine